ArticleFrontiers in pharmacology2025
Multi-omics integration and machine learning-driven construction of an immunogenic cell death prognostic model for colon cancer and functional validation of FCGR2A.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Two decades of immunogenic cell death research: a bibliometric analysis of the 100 most cited publications.Frontiers in oncology · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Immunogenic cell death (ICD) influences tumor immune microenvironment remodeling and immunotherapy response. However, the prognostic value of ICD-related genes in colon cancer has not been systematically clarified. This study aimed to develop an ICD-based prognostic model and explore its association with the immune microenvironment and treatment sensitivity. Methods: Transcriptomic and clinical data of colon adenocarcinoma (COAD) patients were obtained from TCGA and GTEx, with GSE17538 and GSE38832 used as external validation cohorts. Single-cell RNA-seq data from the Colon Cancer Atlas were analyzed to characterize ICD-associated T-cell states. Differentially expressed genes between high and low ICD-score T cells were identified using ssGSEA, followed by WGCNA to select immune-related modules. One hundred seventeen machine-learning model combinations were evaluated to construct the optimal prognostic signature. Immune infiltration was assessed using CIBERSORT, ssGSEA, and ESTIMATE. GSEA explored pathway differences, while drug sensitivity was predicted using pRRophetic. The top-weighted gene was validated through Results: Seven major cell types were identified within the tumor microenvironment. T cells with high and low ICD scores exhibited distinct functional and spatial patterns. WGCNA identified a key module highly correlated with ICD scores, and 51 genes were screened. The Random Survival Forest model yielded a 15-gene ICD-related signature with strong prognostic performance (C-index 0.968 in TCGA; 0.767 and 0.855 in validation cohorts). High-risk patients consistently showed poorer survival ( Conclusion: The 15-gene ICD-based model effectively predicts COAD prognosis, reflects immune microenvironment heterogeneity, and offers insights for individualized treatment planning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.